Ann Lab Med.  2016 Jan;36(1):67-69. 10.3343/alm.2016.36.1.67.

Mutational Analysis of SH2B3 in Korean Patients With BCR-ABL1 Negative Myeloproliferative Neoplasm

• Kim N
• Kim IS
• Chang CL
• Lee EY
• Kim HH
• Song MK
• Shin HJ
• Chung JS

• KMID: 2373501
• DOI: http://doi.org/10.3343/alm.2016.36.1.67

Abstract

No abstract available.

MeSH Terms

Female
Fusion Proteins, bcr-abl/*genetics
Humans
Male
Middle Aged
Mutation
Myeloproliferative Disorders/*genetics
Polycythemia Vera/genetics
Primary Myelofibrosis/genetics
Proteins/*genetics
Thrombocythemia, Essential/genetics
Fusion Proteins, bcr-abl
Proteins

Figure

• 

  Fig. 1 Nucleotide sequence and chromatogram of SH2B3 mutations in Korean patients with BCR-ABL1 negative myeloproliferative neoplasm. (A) Nonsense mutation (c.1711C>T; p.Q571*), (B) missense mutation (c.1703T>C; p.I568T).

Reference

1. Hurtado C, Erquiaga I, Aranaz P, Miguéliz I, García-Delgado M, Novo FJ, et al. LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617F JAK2 mutation. Leuk Res. 2011; 35:1537–1539. PMID: 21794913.

2. Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD Jr, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010; 116:988–992. PMID: 20404132.

3. Lasho TL, Tefferi A, Finke C, Pardanani A. Clonal hierarchy and allelic mutation segregation in a myelofibrosis patient with two distinct LNK mutations. Leukemia. 2011; 25:1056–1058. PMID: 21415853.

4. Ha JS, Jeon DS. Possible new LNK mutations in myeloproliferative neoplasms. Am J Hematol. 2011; 86:866–868. PMID: 21922527.

5. Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol. 2009; 27:6109–6116. PMID: 19901108.

6. Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia. 2010; 24:1713–1718. PMID: 20724988.

7. Koren-Michowitz M, Gery S, Tabayashi T, Lin D, Alvarez R, Nagler A, et al. SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F. Br J Haematol. 2013; 161:811–820. PMID: 23590807.

8. Bersenev A, Wu C, Balcerek J, Tong W. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J Clin Invest. 2008; 118:2832–2844. PMID: 18618018.